Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data reveals treatment patterns for advanced prostate cancer

NCT ID NCT07086651

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records from over 1,300 men with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients actually take the pills apalutamide or enzalutamide when prescribed by their own doctors in routine care. The goal is to understand real-world treatment patterns, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,300 people

The number who actually took part.

Started

Jul 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men with metastatic castration-sensitive prostate cancer who initiated apalutamide or enzalutamide and met eligibility criteria will be included in the study. Patients will be identified from the Flatiron Health electronic health records database.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients diagnosed with metastatic prostate cancer * Initiated apalutamide or enzalutamide for the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Initiation date of first treatment defines the index date. * Index date on or after 1 January 2020 * Evidence of androgen deprivation therapy (ADT) use between 90 days prior to the index date and 6 months following the index date * Age ≥18 years on the index date -≥6 months of clinical activity following the index date, unless the patient died Exclusion Criteria: * Evidence of castration-resistance prior to the index date * Received chemotherapy, androgen receptor pathway inhibitor, radiopharmaceuticals, immunotherapy, PARP inhibitor, or estrogens prior to the index date * Evidence of ADT use between 1 year and 91 days prior to the index date * Had a prior history of other cancers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of the prostate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of the prostate Metastatic castration sensitive prostate cancer (MCSPC) Prostate cancer Prostate neoplasms

Contacts and locations

Locations

  • Pfizer, Inc

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.